Reducing risk for cell therapy manufacturing with a battle-tested electroporation platform

Watch the video or view the poster to learn about:  How choosing a clinically-validated manufacturing platform for critical steps such as cell electroporation can reduce risk during cell therapy manufacturing. The MaxCyte GTx™–a clinically-validated electroporation platform optimized for cell therapy manufacturing. How to address key risk factors during the cell therapy manufacturing process, such as process variability, complexity, and product yield. The importance of robust, expert technical and regulatory support in enhancing risk mitigation

Please enter your email to access content Read now